問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of General Internal Medicine

Division of Radiation Therapy

Division of Hematology & Oncology

Digestive System Department

Division of Thoracic Medicine

Kaoshiung Chang Gung Memorial Hospital of the C.G.M.F.

更新時間：2023-11-06

洪逸平Hung, Yi-Ping
  • Principal Investigator
  • Clinical Trial Experience (year)

Recruiting Trial

119Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

洪逸平

List

194Cases

2018-06-01 - 2020-05-31

Phase I

Completed
A Phase 1A/1B, Open Label, Multiple Dose, Dose Escalation, and Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activities of BGB-290 in Subjects with Advanced Solid Tumors

  • Condition/Disease

    For Participants With Advanced Solid Tumors Failed With Previous Lines of Treatment

  • Test Drug

    BGB-290

Participate Sites
5Sites

Terminated5Sites

2026-09-01 - 2029-03-31

Phase III

Not yet recruiting
A Phase 3, randomized, open-label study (MAPKeeper 301) comparing atebimetinib combined with a modified gemcitabine and nab-paclitaxel regimen versus the standard gemcitabine and nab-paclitaxel regimen for the treatment of patients with metastatic pancreatic ductal adenocarcinoma.

  • Condition/Disease

    Metastatic pancreatic adenocarcinoma

  • Test Drug

    Atebimetinib

Participate Sites
4Sites

Not yet recruiting4Sites

2019-11-01 - 2024-05-13

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
13Sites

Recruiting13Sites

2020-03-01 - 2028-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
8Sites

Recruiting8Sites

2020-07-01 - 2027-07-31

Phase I

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Not yet recruiting1Sites

Recruiting5Sites

2020-08-01 - 2028-06-30

Phase II

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
6Sites

Recruiting6Sites

2020-08-31 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
11Sites

Recruiting11Sites

2020-10-26 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Not yet recruiting6Sites

Recruiting1Sites

2021-04-01 - 2024-03-15

Phase I

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2021-05-03 - 2022-07-07

Phase I

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

1 2 3 4 5 20
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB